Source: http://www.google.com/patents/US4643715?dq=3691140
Timestamp: 2016-05-05 05:02:32
Document Index: 13611338

Matched Legal Cases: ['art 6200', 'art 5700', 'art 8100', 'art 6700', 'art 8900', 'art 8100']

Patent US4643715 - Artificial organ and method for manufacture thereof - Google PatentsSearch Images Maps Play YouTube News Gmail Drive More »Sign inPatentsMedical permeating membranes in a zone through which a body fluid flows, said membranes having lateral surfaces in said zone, comprising permeable membranes of regenerated cellulose and a film of a fat-soluble vitamin and glycerin on said lateral surfaces of said membranes in said zone for flow of body...http://www.google.com/patents/US4643715?utm_source=gb-gplus-sharePatent US4643715 - Artificial organ and method for manufacture thereofAdvanced Patent SearchPublication numberUS4643715 APublication typeGrantApplication numberUS 06/878,059Publication dateFeb 17, 1987Filing dateJun 24, 1986Priority dateSep 9, 1982Fee statusPaidAlso published asDE3378461D1, EP0103816A2, EP0103816A3, EP0103816B1, US4588407, US4634447Publication number06878059, 878059, US 4643715 A, US 4643715A, US-A-4643715, US4643715 A, US4643715AInventorsKeinosuke Isono, Keiji NaoiOriginal AssigneeTerumo Kabushiki KaishaExport CitationBiBTeX, EndNote, RefManPatent Citations (2), Referenced by (43), Classifications (18), Legal Events (4) External Links: USPTO, USPTO Assignment, EspacenetArtificial organ and method for manufacture thereof
US 4643715 AAbstract
This invention is directed to a method for the manufacture of an artificial organ wherein the organic solvent is at least one member selected from the group consisting of a chlorofluorohydrocarbon, a fluorohydrocarbon and a lower alcohol. This invention is directed to a method for the manufacture of an artificial organ wherein the concentration of the fat-soluble vitamin in the solution thereof in the organic solvent is in the range of from 0.01 to 10 w/v%. This invention is further directed to a method for the manufacture of an artificial organ wherein the drying of the deposited solution is effected by passing through the aforementioned body fluid-flowing zone a gas inert to the aforementioned fat-soluble vitamin at a temperature in the range of from 10� to 80� C. This invention is also directed to a method for the manufacture of a sterilized artificial organ wherein the aforementioned physiologically harmless liquid comprises water, physiological saline solution, or an aqueous glycerin solution.
The fat-soluble vitamin is dissolved at a concentration in the range of from 0.01 to 10 w/v %, preferably from 0.05 to 2.0 w/v %, in an organic solvent. The solution thus prepared is caused to flow into the body fluid-flowing zone of the artificial organ (the blood-flowing zone in the case of the artificial kidney illustrated in FIG. 1 and FIG. 2) and allowed to remain in contact with the zone for a stated period such as, for example, 30 seconds to 60 minutes, preferably 1 to 10 minutes so as to have the inner surfaces of the parts in the aforementioned zone such as, for example, the inner surfaces of the tube 14, the cavity defined by the header 10 and the potting ring 6, the hollow fiber, the cavity defined by the header 11 and the potting ring 7, and the tube 15 amply wetted with the aforementioned fat-soluble vitamin. A film of the aforementioned fat-soluble vitamin is deposited on the aforementioned surfaces by subsequently discharging the solution from the artificial organ and introducing into the artificial organ a gas inert to the fat-soluble vitamin such as, for example, air, nitrogen or carbon dioxide gas at a temperature in the range of from 10� to 80� C., preferably from 15� to 30� C. thereby expelling the organic solvent by distillation from the solution. When necessary, the artificial organ may be rinsed with water. In this case, the film of the fat-soluble vitamin may be formed particularly in the portion packed with the permeating membranes. Especially in the artificial organ incorporating regenerated cellulose membranes which are liable to induce hemodialysis leukopenia, a notable effect in curbing this detestable phenomenon can be obtained by having the film of fat-soluble vitamin deposited preponderantly on the portion packed with the permeating membranes. Where such permeating membranes are made of regenerated cellulose, particularly regenerated cellulose of the cuprammonium process, the aforementioned solution of fat-soluble vitamin in the organic solvent may additionally incorporate glycerin therein. The addition of glycerin serves the purpose of enhancing the hydrophilicity of the permeating membrane. It is, therefore, effective in artificial organs such as artificial kidney and artificial liver which are required to use hydrophilic permeating membranes. The concentration of glycerin in the aforementioned solution is in the range of from 0.1 to 10 w/v %, preferably from 1 to 5 w/v %.
TABLE 3______________________________________(Vitamin E 1.0%)WBC            PLT            HCT         PIC              PIC         PICTime  /mm3         (%)      �104 /mm3                          (%)    %    (%)______________________________________Start 6200    100.0    61.3    100.0  43.3 100.0 5 min. 5710    92.1     57.3    93.5   39.4 91.010    5530    89.2     56.3    91.8   39.9 92.115    5520    89.0     54.8    89.4   39.2 90.520    5200    83.9     53.4    97.1   39.1 90.330    5240    84.5     50.6    82.5   39.7 91.745    5150    83.1     46.7    76.1   39.5 91.2 1 hr. 6030    97.3     46.1    75.2   38.8 89.6 2    7380    119.0    42.4    69.2   39.3 90.7 3    6650    107.3    34.9    56.9   41.0 94.7 4    6710    108.2    37.1    60.5   41.3 95.4 5    7640    123.2    37.9    61.8   40.8 94.2 6    7490    120.8    36.8    60.0   39.9 92.1______________________________________ PIC means percent of initial count.
TABLE 4______________________________________(Vitamin E. 0.1%)WBC            PLT            HCT         PIC              PIC         PICTime  /mm3         (%)      �104 /mm3                          (%)    %    (%)______________________________________Start 5700    100.0    61.6    100.0  45.4 100.0 5 min. 5340    93.7     53.2    86.4   40.8 89.910    5410    94.9     54.4    88.3   40.3 88.815    5030    88.2     53.9    87.5   40.6 89.420    4780    78.6     47.1    76.5   40.6 89.430    4630    81.2     42.4    68.8   42.2 93.045    5080    89.1     38.8    63.0   40.2 88.5 1 hr. 5040    88.4     37.9    61.5   40.5 89.2 2    6320    110.9    32.2    52.3   39.5 87.0 3    7640    134.0    33.8    54.9   39.8 87.7 4    9750    171.1    34.3    55.7   39.1 86.1 5    10590   185.5    32.8    52.4   40.3 88.8 6    11870   208.2    29.9    48.5   39.0 85.9______________________________________
TABLE 5______________________________________(Vitamin E none)WBC            PLT            HCT         PIC              PIC         PICTime  /mm3         (%)      �104 /mm3                          (%)    %    (%)______________________________________Start 8100    100.0    86.4    100.0  44.4 100.0 5 min. 4230     52.2    79.8    92.4   39.9 89.910    3850     47.5    76.8    88.9   39.2 88.315    4100     50.6    73.2    84.7   41.2 92.820    4520     55.8    71.4    82.6   40.3 90.830    6820     84.2    69.8    80.8   38.4 86.545    6870     84.8    66.7    77.2   39.4 88.7 1 hr. 8790    108.5    64.8    75.0   38.9 87.6 2    11520   142.2    54.7    63.3   39.7 89.4 3    13720   169.4    47.8    55.3   38.2 86.5 4    18130   223.8    50.3    58.2   38.7 87.2 5    22500   277.8    52.3    60.5   37.1 83.6 6    22690   280.1    55.7    64.5   36.6 82.4______________________________________
TABLE 6______________________________________(Vitamin E 1.0%)WBC            PLT            HCT         PIC              PIC         PICTime  /mm3         (%)      �104 /mm3                          (%)    %    (%)______________________________________Start 6700    100.0    71.0    100.0  48.0 100.0 5 min. 5830     87.0    68.0    95.8   42.8 89.210    5050     75.4    66.0    93.6   41.8 87.115    4940     73.7    68.5    96.5   44.7 93.120    4950     73.9    63.5    89.4   44.6 92.930    5930     88.5    59.5    83.8   41.3 86.045    6590     98.4    55.1    77.6   43.7 91.0 1 hr. 7650    114.2    58.2    82.0   43.9 91.5 2    9380    140.0    51.8    73.0   43.0 89.6 3    10400   155.2    43.8    61.7   43.4 90.4 4    9950    148.5    36.8    51.8   44.4 92.5 5    10740   160.3    38.5    54.2   43.8 91.3 6    11690   174.5    39.3    55.4   42.7 89.0______________________________________ PIC means percent of initial count.
TABLE 7______________________________________(Vitamin E 0.1%)WBC            PLT            HCT         PIC              PIC         PICTime  /mm3         (%)      �104 /mm3                          (%)    %    (%)______________________________________Start 8900    100.0    85.7    100.0  51.7 100.0 5 min. 8210    92.2     93.0    108.5  42.8 82.710    6700    75.2     85.3    99.5   46.3 89.615    6110    68.7     79.7    93.0   47.4 91.720    6080    68.3     74.8    87.3   46.8 90.530    6780    76.2     63.3    73.9   47.3 91.545    7660    85.4     57.8    67.4   48.3 93.4 1 hr. 8180    91.9     53.9    62.9   47.4 91.6 2    7850    88.2     46.5    54.3   48.1 93.0 3    10890   122.4    38.9    45.4   45.3 87.2 4    13120   147.4    32.5    37.9   45.3 87.6 5    13720   154.2    36.6    42.7   45.6 88.2 6    13700   153.9    39.2    45.7   43.4 83.9______________________________________
TABLE 8______________________________________(Vitamin E none)WBC            PLT            HCT         PIC              PIC         PICTime  /mm3         (%)      �104 /mm3                          (%)    %    (%)______________________________________Start 8100    100.0    86.4    100.0  44.4 100.0 5 min. 4230     52.2    79.8    92.4   39.9 89.910    3850     47.5    76.8    88.9   39.2 88.315    4100     50.6    73.2    84.7   41.2 92.820    4520     55.8    71.4    82.6   40.3 90.830    6820     84.2    69.8    80.8   38.4 86.545    6870     84.8    66.7    77.2   39.4 88.7 1 hr. 8790    108.5    64.8    75.0   38.9 87.6 2    11520   142.2    54.7    63.3   39.7 89.4 3    13720   169.4    47.8    55.3   38.2 86.5 4    18130   223.8    50.3    58.2   38.7 87.2 5    22500   277.8    52.3    60.5   37.1 83.6 6    22690   280.1    55.7    64.5   36.6 82.4______________________________________
TABLE 9______________________________________(Vitamin E 0.5%)WBC            PLT            HCT         PIC              PIC         PICTime  /mm3         (%)      �104 /mm3                          (%)    %    (%)______________________________________ 0    7870    100.0    84.4    100.0  46.7 100.0 5    8030    102.0    84.8    100.5  41.0 87.810    7290     92.6    85.0    100.7  44.7 95.715    6550     83.2    81.2    96.2   42.4 90.820    6300     80.1    77.0    91.2   42.3 90.630    7290     92.6    72.0    85.3   42.7 91.445    8000    101.1    67.1    79.5   41.1 88.060    8930    113.5    62.8    74.4   41.4 88.7120   11800   149.9    62.1    73.6   39.5 84.6______________________________________
TABLE 10______________________________________(Vitamin E none)WBC            PLT            HCTTime          PIC              PIC         PIC(min) /mm3         (%)      �104 /mm3                          (%)    %    (%)______________________________________ 0    8880    100.0    66.7    100.0  47.0 100.0 5    7160    80.6     65.1    97.6   39.5 84.010    5900    66.4     63.5    95.2   40.6 86.415    4480    50.5     60.7    91.0   40.8 86.820    5030    56.6     58.5    87.7   40.5 86.230    6530    73.5     52.9    79.3   40.4 86.0 45.  7790    87.7     53.1    79.6   40.4 86.060    8340    93.9     49.7    74.5   40.0 85.1120   9610    108.2    45.4    68.1   38.6 82.1______________________________________
Patent CitationsCited PatentFiling datePublication dateApplicantTitleUS4211602 *May 4, 1978Jul 8, 1980Brumfield Robert CSurface treatment for blood dialysis cartridgesUS4354933 *Feb 23, 1981Oct 19, 1982Lester James PImplantable artificial kidney* Cited by examinerReferenced byCiting PatentFiling datePublication dateApplicantTitleUS4994084 *Jun 23, 1989Feb 19, 1991Brennan H GeorgeReconstructive surgery method and implantUS5212000 *Mar 11, 1991May 18, 1993The Dow Chemical CompanyMethod for providing an inner-skinned functionalized coating on the lumen-defining surface of a hollow tubeUS5421815 *Dec 14, 1993Jun 6, 1995Nof CorporationMethod for blood dialysis using anticoagulent compositionUS5433909 *Mar 12, 1993Jul 18, 1995Atrium Medical CorporationMethod of making controlled porosity expanded polytetrafluoroethylene productsUS5509895 *Jun 5, 1995Apr 23, 1996Nof CorporationAir trap chamber device for blood dialysis circuit containing an anticoagulant compositionUS5605835 *Jan 20, 1995Feb 25, 1997Regents Of The University Of MinnesotaBioreactor device with application as a bioartificial liverUS5637081 *Jun 5, 1995Jun 10, 1997Nof CorporationAnticoagulant composition for use in blood dialysis circuitUS5827904 *Sep 27, 1996Oct 27, 1998Hahn; DavidMedical implant compositionUS5861033 *Jan 30, 1997Jan 19, 1999Atrium Medical CorporationMethod of making controlled porosity expanded polytetrafluoroethylene products and fabricationUS5980799 *Jun 16, 1998Nov 9, 1999Atrium Medical CorporationMethods of making controlled porosity expanded polytetrafluoroethylene products and fabricationUS5981211 *Oct 7, 1996Nov 9, 1999Regents Of The University Of MinnesotaMaintaining cells for an extended time by entrapment in a contracted matrixUS5993406 *May 14, 1997Nov 30, 1999Cedars-Sinai Medical CenterArtificial gutUS6001288 *Dec 24, 1997Dec 14, 1999Terumo Kabushiki KaishaProcess for producing a hollow fiber membrane having a hydrophobic coatingUS6102898 *Nov 2, 1995Aug 15, 2000Becton Dickinson & CompanyRadiation compatible lubricant for medical devicesUS6379619Apr 19, 1999Apr 30, 2002Cedars-Sinai Medical CenterArtificial gutUS6544424Mar 17, 2000Apr 8, 2003Refined Technology CompanyFluid filtration systemUS7871462Jan 18, 2011Baxter International Inc.Dialysis systems having air separation chambers with internal structures to enhance air removalUS7892331Feb 22, 2011Baxter International Inc.Dialysis systems having air separation chambers with internal structures to enhance air removalUS7892332Feb 22, 2011Baxter International Inc.Dialysis systems having air traps with internal structures to enhance air removalUS7988768Aug 2, 2011Baxter International Inc.Dialysis systems having spiraling fluid air separation chambersUS8025714Sep 27, 2011Baxter International Inc.Dialysis systems and methods having vibration-aided air removalUS8025716Sep 27, 2011Baxter International Inc.Fluid delivery systems and methods having floating baffle aided air removalUS8080091Dec 20, 2011Baxter International Inc.Dialysis systems and methods including cassette with fluid heating and air removalUS8114276Oct 23, 2008Feb 14, 2012Baxter International Inc.Personal hemodialysis systemUS8123947Oct 22, 2007Feb 28, 2012Baxter International Inc.Priming and air removal systems and methods for dialysisUS8221529Nov 21, 2011Jul 17, 2012Baxter InternationalDialysis systems and methods including cassette with air removalUS8323492Aug 19, 2011Dec 4, 2012Baxter International Inc.Hemodialysis system having clamping mechanism for peristaltic pumpingUS8329030Aug 19, 2011Dec 11, 2012Baxter International Inc.Hemodialysis system with cassette and pinch clampUS8382711Feb 26, 2013Baxter International Inc.Intravenous pumping air management systems and methodsUS8444587Sep 24, 2008May 21, 2013Baxter International Inc.Fluid and air handling in blood and dialysis circuitsUS8834403May 14, 2013Sep 16, 2014Baxter International Inc.Fluid and air handling in blood and dialysis circuitsUS8834719Dec 19, 2011Sep 16, 2014Baxter International Inc.Personal hemodialysis systemUS8932469Jan 9, 2012Jan 13, 2015Baxter International Inc.Personal hemodialysis system including priming sequence and methods of sameUS9084858Feb 21, 2013Jul 21, 2015Baxter International Inc.Intravenous pumping air management systems and methodsUS20090084718 *Oct 1, 2007Apr 2, 2009Baxter International Inc.Dialysis systems having air traps with internal structures to enhance air removalUS20090084719 *Oct 1, 2007Apr 2, 2009Baxter International Inc.Dialysis systems having air separation chambers with internal structures to enhance air removalUS20090084721 *Oct 1, 2007Apr 2, 2009Baxter International Inc.Dialysis systems having air separation chambers with internal structures to enhance air removalUS20090088675 *Sep 24, 2008Apr 2, 2009Baxter International Inc.Fluid and air handling in blood and dialysis circuitsUS20090101576 *Oct 22, 2007Apr 23, 2009Baxter International Inc.Priming and air removal systems and methods for dialysisUS20110092895 *Apr 21, 2011Baxter International Inc.Dialysis systems having spiraling fluid air separation chambersUS20110137236 *Jun 9, 2011Baxter International Inc.Fluid delivery systems and methods having floating baffle aided air removalUS20110137237 *Jun 9, 2011Baxter International Inc.Dialysis systems and methods having vibration-aided air removalUS20110144557 *Jun 16, 2011Baxter International Inc.Dialysis systems and methods including cassette with fluid heating and air removal* Cited by examinerClassifications U.S. Classification604/4.01, 210/646, 427/2.3, 210/645, 210/500.27, 210/500.29, 422/44International ClassificationB01D63/02, B01D65/02, B01D67/00, A61M1/18Cooperative ClassificationB01D2321/32, B01D65/022, B01D67/0088, B01D63/021European ClassificationB01D63/02B, B01D65/02B, B01D67/00R14Legal EventsDateCodeEventDescriptionAug 10, 1990FPAYFee paymentYear of fee payment: 4Aug 1, 1994FPAYFee paymentYear of fee payment: 8Aug 4, 1998FPAYFee paymentYear of fee payment: 12Aug 28, 2002ASAssignmentOwner name: ASAHI MEDICAL CO., LTD., JAPANFree format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:TERUMO KABUSHIKI KAISHA (AKA TERUMO CORPORATION);REEL/FRAME:013231/0052Effective date: 20020725RotateOriginal ImageGoogle Home - Sitemap - USPTO Bulk Downloads - Privacy Policy - Terms of Service - About Google Patents - Send FeedbackData provided by IFI CLAIMS Patent Services